Skip to main content
Clinical Trials/NCT01461434
NCT01461434
Unknown
Phase 4

Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients

Medical University of Graz1 site in 1 country82 target enrollmentNovember 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Medical University of Graz
Enrollment
82
Locations
1
Primary Endpoint
Time to first diagnosis of atrial fibrillation
Last Updated
10 years ago

Overview

Brief Summary

Atrial fibrillation (AF) is the most common clinical arrhythmia. AF is associated with increased risk for stroke due to blood clots formed in the fibrillating atria. Some patient characteristics increase the likelyhood of AF and at the same time the risk of stroke when AF has developed. To reduce the risk of stroke, anticoagulation therapy is recommended in patients with AF and risk factors (such as high blood pressure, diabetes, vessel disease). However, occasional (paroxysmal) AF may occur without symptoms and remain undetected, leaving patients at risk.

Aim of the prospective randomized study is to compare two management strategies for patients at increased risk for AF but without a known history of AF. Patients are seen regularly (monthly, then quarterly) for follow-up (incl. ECG recording and blood sample). One group of patients additionally receives a subcutaneous implantation of a loop recorder for continuous rhythm monitoring, while the control group remains on standard follow-up. Observation period is one year (optional extension for 3 years). The time to first diagnosis of AF is compared between groups, blood samples are analyzed for potential biomarkers of AF.

Registry
clinicaltrials.gov
Start Date
November 2011
End Date
January 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Medical University of Graz
Responsible Party
Principal Investigator
Principal Investigator

Frank R Heinzel, MD, PhD

Associate Professor Frank R. Heinzel, MD, PhD

Medical University of Graz

Eligibility Criteria

Inclusion Criteria

  • CHA2DS2-VASc risk score \>= 4\*
  • 18 years or older

Exclusion Criteria

  • known history of atrial fibrillation
  • implanted rhythm device
  • pre-existing indication for oral anticoagulation
  • (\*)CHA2DS2-VASc: C - chronic heart failure (1 point); H - hypertension (1 point); A - age \>= 75 years (2 points); D - diabetes (1 point); S - stroke (2 points); V - vascular disease (1 point); A - age \>=65 and \< 75 years (1 point); Sc - sex category (female) (1 point) ;

Outcomes

Primary Outcomes

Time to first diagnosis of atrial fibrillation

Time Frame: 12 months

Secondary Outcomes

  • Death(12 months)
  • Stroke(12 months)
  • Hospitalizations(12 months)
  • Change in NTproBNP serum level associated with occurrence of atrial fibrillation(Baseline (0 months), 1,2,3,4,5,6,9 and 12 months)
  • Time to change in therapy based on the diagnosis of atrial fibrillation(Baseline (0 months), 1,2,3,4,5,6,9 and 12 months)

Study Sites (1)

Loading locations...

Similar Trials